Improving the Efficacy of Immune-therapies for Melanoma Patients

In his recent commentary “Long-term survival with anti-PD-1-based immunotherapy, but what is the best approach?” in the Lancet Oncology Prof. Middleton, Cancer Research UK Oxford Centre Co-Director and Head of the Department of Oncology at the University of Oxford, discusses how the clinical community should look to build on the already transformative use of immune therapies to treat patients with melanoma.

Having more than doubled life expectancies for late-stage metastatic melanoma patients, there still remains significant potential for improving how and when these novel therapeutics are deployed, for which patients they are prescribed, and how to limit the side effects of these agents. These questions form the focus of efforts of cancer researchers across Oxford,  from  fundamental laboratory based research to national collaborations, and to clinical trials that are improving the lives of patients treated at the Oxford University Hospitals Foundation Trust and across the UK.